ENTERA BIO LTD. Operating Income
ENTERA BIO LTD. (ENTX) reported Operating Income of -$4.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-07
- ENTERA BIO LTD. operating income (loss) for the quarter ending 2026-06-30 was -$4.56M.
- ENTERA BIO LTD. operating income (loss) for the quarter ending 2026-03-31 was -$3.54M.
- ENTERA BIO LTD. operating income (loss) for the quarter ending 2025-12-31 was -$3.04M.
- ENTERA BIO LTD. operating income (loss) for the quarter ending 2025-09-30 was -$3.26M.
- ENTERA BIO LTD. operating income (loss) for fiscal 2025 was -$11.53M.
- ENTERA BIO LTD. operating income (loss) for fiscal 2024 was -$9.59M.
- ENTERA BIO LTD. operating income (loss) for fiscal 2023 was -$8.89M.
- ENTERA BIO LTD. operating income (loss) for fiscal 2022 was -$13.02M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.56M 10-Q · filed 2026-08-07 | -$8.10M 10-Q · filed 2026-08-07 | -$11.14M derived: sum of 3 quarters · filed 2026-08-07 | -$14.40M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$3.54M 10-Q · filed 2026-05-08 | -$6.58M derived: sum of 2 quarters · filed 2026-05-08 | -$9.84M derived: sum of 3 quarters · filed 2026-05-08 | -$12.51M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$6.30M derived: sum of 2 quarters · filed 2026-03-27 | -$8.97M derived: sum of 3 quarters · filed 2026-08-07 | -$11.53M 10-K · filed 2026-03-27 |
| 2025-09-30 | -$3.26M 10-Q · filed 2025-11-14 | -$5.92M derived: sum of 2 quarters · filed 2026-08-07 | -$8.49M 10-Q · filed 2025-11-14 | -$10.82M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$2.67M 10-Q · filed 2026-08-07 | -$5.23M 10-Q · filed 2026-08-07 | -$7.57M derived: sum of 3 quarters · filed 2026-08-07 | -$10.59M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$2.56M 10-Q · filed 2026-05-08 | -$4.90M derived: sum of 2 quarters · filed 2026-05-08 | -$7.92M derived: sum of 3 quarters · filed 2026-05-08 | -$10.09M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$5.36M derived: sum of 2 quarters · filed 2026-03-27 | -$7.52M derived: sum of 3 quarters · filed 2026-03-27 | -$9.59M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$3.02M 10-Q · filed 2025-11-14 | -$5.19M derived: sum of 2 quarters · filed 2025-11-14 | -$7.25M 10-Q · filed 2025-11-14 | -$9.21M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$2.17M 10-Q · filed 2025-08-08 | -$4.23M 10-Q · filed 2025-08-08 | -$6.19M derived: sum of 3 quarters · filed 2025-08-08 | -$8.58M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | -$2.06M 10-Q · filed 2025-05-09 | -$4.03M derived: sum of 2 quarters · filed 2025-05-09 | -$6.41M derived: sum of 3 quarters · filed 2025-05-09 | -$8.74M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$4.35M derived: sum of 2 quarters · filed 2025-03-28 | -$6.68M derived: sum of 3 quarters · filed 2025-03-28 | -$8.89M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$2.39M 10-Q · filed 2024-11-08 | -$4.72M derived: sum of 2 quarters · filed 2024-11-08 | -$6.93M 10-Q · filed 2024-11-08 | -$10.00M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | -$2.33M 10-Q · filed 2024-08-09 | -$4.54M 10-Q · filed 2024-08-09 | -$7.61M derived: sum of 3 quarters · filed 2024-08-09 | -$10.47M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | -$2.21M 10-Q · filed 2024-05-10 | -$5.28M derived: sum of 2 quarters · filed 2024-05-10 | -$8.14M derived: sum of 3 quarters · filed 2024-05-10 | -$11.39M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$5.93M derived: sum of 2 quarters · filed 2024-03-08 | -$9.18M derived: sum of 3 quarters · filed 2024-03-08 | -$13.02M 10-K · filed 2024-03-08 |
| 2022-09-30 | -$2.87M 10-Q · filed 2023-11-14 | -$6.11M derived: sum of 2 quarters · filed 2023-11-14 | -$9.95M 10-Q · filed 2023-11-14 | -$14.04M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$3.25M 10-Q · filed 2023-08-11 | -$7.08M 10-Q · filed 2023-08-11 | -$11.17M derived: sum of 3 quarters · filed 2023-08-11 | -$14.39M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$3.83M 10-Q · filed 2023-05-05 | -$7.92M derived: sum of 2 quarters · filed 2023-05-05 | -$11.14M derived: sum of 3 quarters · filed 2023-05-05 | -$13.71M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | -$4.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$7.31M derived: sum of 2 quarters · filed 2023-03-31 | -$9.88M derived: sum of 3 quarters · filed 2023-03-31 | -$12.22M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$3.22M 10-Q · filed 2022-11-10 | -$5.79M derived: sum of 2 quarters · filed 2022-11-10 | -$8.13M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$2.57M 10-Q · filed 2022-08-11 | -$4.91M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$2.34M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$11.17M 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |